第一金融網主辦
»您現在的位置: 第一金融網 >> 財經金融 >> 文傳商訊 >> 正文

Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day

2019/11/17 18:58:25  文章來源:文傳商訊  作者:文傳商訊
文章簡介: Growthinthenear-andmedium-termwillalsobedrivenbytheexpansionofTakeda’scurrent14globalgrowthbrands Sustainedinnovationbeyond2024basedona

Growth in the near- and medium-term will also be driven by the expansion of Takeda’s current 14 global growth brands

Sustained innovation beyond 2024 based on a promising early stage pipeline and novel research platforms intended to provide transformative benefit for targeted populations with high unmet needs

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first, patient-centric strategy, diverse portfolio of approved medicines and its R&D engine is expected to drive the company’s near-term and sustained growth.

In the near-term, Takeda expects that its 14 current global growth brands will generate significant momentum enabled by at least 20 additional indications and major market expansions through FY24. In the same time period, the organization anticipates delivering 12 new molecular entities with the potential for 14 launches, representing best-in-class or first-in-class therapies across its core areas of focus.

Looking ahead to FY25 and beyond, Takeda’s transformative R&D engine comprising internal research capabilities and external partnerships is expected to advance a steady stream of next-generation therapies based on human validated targets, diverse modalities, and new platform capabilities, including those in cell therapy, gene therapy and data sciences.

2019 R&D Day Agenda
The meeting will feature the following presentations and speakers:

Welcome and Opening Remarks, Sheelagh Cawley-Knopf, Head, R&D Global Portfolio Strategy

Takeda: A Global Values-Based, R&D-Driven Biopharmaceutical Leader, Christophe Weber, President & CEO

Translating Science into Highly Innovative, Life-changing Medicines, Andy Plump, President, R&D

Oncology and Cell Therapies with Spotlight on CAR-NK, Chris Arendt, Head, Oncology Drug Discovery Unit

Spotlight on Oncology Opportunities: TAK-788, Rachael Brake, Global Program Leader, Oncology

Spotlight on Oncology Opportunities: Pevonedistat, Phil Rowlands, Head, Oncology Therapeutic Area Unit

Rare Diseases & Gene Therapy, Dan Curran, Head, Rare Diseases Therapeutic Area Unit

Spotlight on Orexin2R Agonists, Deborah Hartman, Global Program Leader, Neuroscience

Therapeutic Area Focus in GI with Spotlight on Celiac Disease, Asit Parikh, Head, GI Therapeutic Area Unit

Webcast Details and Other Upcoming Events
Takeda invites the investment community, media and general public to watch a live webcast of today’s R&D Day event from 12:30 p.m. to 4:00 p.m. EST. To join this live webcast or the others noted below, view related materials or watch video replays, please visit the FY19 Special IR Events section of our website.

Following today’s R&D Day in New York, Takeda will host a Plasma-Derived Therapies Day on November 15, 2019 in Covington, Georgia from 11:15 a.m. to 3:45 p.m. EST. This will include a presentation of our Plasma-Derived Therapies R&D strategy and plans.

Takeda will host a combined R&D Day and Plasma-Derived Therapies Day on November 21, 2019 in Tokyo from 11:00 a.m. to 5:00 p.m. JST.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com

Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takeda’s estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product canddates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s), any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information—D. Risk Factors” in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.

分享到:
第一金融網免責聲明:
1、本網站中的文章(包括轉貼文章)的版權僅歸原作者所有,若作者有版權聲明的或文章從其它網站轉載而附帶有原所有站的版權聲明者,其版權歸屬以附帶聲明為準。
2、文章來源為均為其它媒體的轉載文章,我們會盡可能注明出處,但不排除來源不明的情況。轉載是處于提供更多信息以參考使用或學習、交流、科研之目的,不用于 商業用途。轉載無意侵犯版權,如轉載文章涉及您的權益等問題,請作者速來電話和函告知,我們將盡快處理。來信:fengyueyoubian#sina.com (請將#改為@)。
3、本網站所載文章、數據、網友投稿等內容純屬作者個人觀點,僅供投資者參考,并不構成投資建議,與第一金融網站無關。投資者據此操作,風險自擔。如對本文內容有疑義,請及時與我們聯系。
發表評論

【發表評論】(網友評論內容只代表網友觀點,與本站立場無關。
 姓 名:
 評 分: 1分 2分 3分 4分 5分
 評論內容:
驗證碼:   *
  • 請遵守《互聯網電子公告服務管理規定》及中華人民共和國其他各項有關法律法規。
  • 嚴禁發表危害國家安全、損害國家利益、破壞民族團結、破壞國家宗教政策、破壞社會穩定、侮辱、誹謗、教唆、淫穢等內容的評論 。
  • 用戶需對自己在使用本站服務過程中的行為承擔法律責任(直接或間接導致的)。
  • 本站管理員有權保留或刪除評論內容。
  • 評論內容只代表網友個人觀點,與本網站立場無關。
  • 全站精選
    [新聞]  搭載一億像素?小米MIX 4 5G曝光:完美
     媽祖真有身份證號 是350321096003237001(圖)
    [銀行]  中行湖南離職員工當掮客:與前同事合謀套取資金6
     中國銀保監會回應銀行擠兌: 處置方式多元、風險
    [股票]  月內北上資金凈流入逾345億 近八成凈買入活躍股
     欠5167萬廣告費 金嗓子創始人被“限制消費”
    [基金]  固收打底權益增強 華夏鼎泓債券10月28日起發行
     200余家上市公司獲真金白銀增持 有你的票嗎?
    [保險]  199元買的“戀愛保險” 三年過去了真能獲賠嗎?
     人保車險理賠時間規定
    [期貨]  中國商務部:上周豬肉批發價格下降1.9%
     國慶節后國內油價或迎“三連漲”
    [股評]  機構強推買入 六股成搖錢樹(10/14)
     六大券商下周一看好六大板塊(10/14)
    [港股]  阿里巴巴香港上市焦點十問:打新能不能有肉吃?
     阿里巴巴擬定港股發行價上限188港元 最多可募千
    [美股]  曝Google秘密收集百萬美國人健康信息
     比爾蓋茨批評沃倫富人稅: 收我1000億,我還剩多
    [外匯]  發生了什么?人民幣匯率漲700點 大逆轉前曾小幅
     華爾街突遭“美元荒” 本周重點關注歐美制造業P
    [債券]  中國擬進行15年來首次歐元債發行
     中國人民銀行將于11月7日在香港發300億元央票
    [黃金]  中國央行黃金儲備十連漲 多國央行加入購金行列
     2020庚子鼠年賀歲銀條哪里預約?怎么購買?
    [理財]  圓明園馬首是怎么做成的?專家給圓明園馬首拍了
     “帶貨”行業平均薪資破萬元 收入兩極分化嚴重
    [信托]  信托頻頻“踩雷”上市公司
     跌破8% 集合信托收益或繼續下跌
    [房產]  10月份中國70城房價:一二三線城市房價環比漲幅
     今年四季度中國房企高管上演離職潮 年底業績壓力
    [汽車]  特斯拉正式獲中國工信部量產許可
     特斯拉正式獲得中國工信部量產許可
  • 此欄目下沒有推薦文章
  • | 設為首頁 | 加入收藏 | 關于我們 | 友情鏈接 | 版權申明 | 文章列表 | 網站地圖 | 征稿啟事 | 廣告服務 | 意見反饋 |

    Copyright©2006-2027 afinance.cn All Rights Reserved 版權所有·第一金融網 ,未經授權禁止復制或建立鏡像,否則將依法追究法律責任!

    聲明:我們不做任何形式的代客理財及投資指導,凡是以第一金融網名義做股票推薦的行為均屬違法!

    廣告商的言論與行為均與第一金融網無關!股市有風險,投資需謹慎。

    合作郵箱:[email protected] 合作電話:18678839953 點擊這里給我發消息

    斯诺克英锦赛2018转播 二分彩规律 华夏网赚论坛 东京快乐8app 福建22选5走势图1000期 幸运农场能在线购买么 浙江体彩6 1历史开奖结果 捕鱼游戏赚钱平台 2019年英超联赛赛程 苹果填大坑app 北京pk10官网开奖视频